BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:14 PM
 | 
Feb 16, 2017
 |  BC Week In Review  |  Company News  |  Deals

Bial-Portela, Neurocrine Biosciences deal

Bial-Portela granted Neurocrine Biosciences exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370). Bial-Portela will receive $30 million up front and is eligible for up to $115 million in milestones, plus 37% of net sales in...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >